Cargando…
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
Pustular and erythrodermic psoriasis are rare and difficult-to-treat conditions. It has recently been shown that interleukin (IL)-17 inhibitors can be very effective among patients with these forms of psoriasis; however, the potential of IL-23 inhibitors is largely unknown. The aim of this multicent...
Autores principales: | Avallone, Gianluca, Maronese, Carlo Alberto, Murgia, Giulia, Carrera, Carlo Giovanni, Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Alberti-Violetti, Silvia, Quaglino, Pietro, Ribero, Simone, Marzano, Angelo Valerio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962195/ https://www.ncbi.nlm.nih.gov/pubmed/36836196 http://dx.doi.org/10.3390/jcm12041662 |
Ejemplares similares
-
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023) -
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022) -
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022) -
Pustular Psoriasis: From Pathophysiology to Treatment
por: Genovese, Giovanni, et al.
Publicado: (2021) -
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)